Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 661 matching trials from the live ClinicalTrials.gov search.
Conditions
Neonatal Seizure, Epilepsy, Seizures, Inflammatory Response
Interventions
Blood draw, Survey
Diagnostic Test · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Day to 4 Days
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
Oakland, California • San Francisco, California • Boston, Massachusetts + 1 more
Conditions
Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
Interventions
Cannabidiol Oral Solution [Epidiolex]
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 65 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
12
States / cities
Aurora, Colorado • New Haven, Connecticut • Gainesville, Florida + 9 more
Conditions
Brain Injuries, Acute, Brain Injuries, Traumatic, Brain Ischemia, Brain Hypoxia, Hypoxia-Ischemia, Brain, Heart Arrest, Stroke, Intracranial Hemorrhages, Coma, Persistent Vegetative State
Interventions
Phenobarbital Sodium Injection, Levetiracetam, Lacosamide Injectable Product, Valproate Sodium, Fosphenytoin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Months to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed Phase 2 Interventional Results available

Amantadine to Speed Awakening After Cardiac Arrest

NCT02486211
Conditions
Coma, Heart Arrest, Anoxia
Interventions
Amantadine, Placebo
Drug
Lead sponsor
Jon Rittenberger, MD
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Portland, Maine • Boston, Massachusetts • Pittsburgh, Pennsylvania
Conditions
Seizures, Seizures, Focal, Seizure, Partial Onset, Seizure Disorder, Partial, Seizure, Partial, Epilepsies, Partial, Epilepsy
Interventions
Zonisamide Oral Product
Drug
Lead sponsor
Azurity Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Memphis, Tennessee
Conditions
Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epileptic Syndromes
Interventions
XEN496
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
1 Month to 6 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Tacoma, Washington
Conditions
Partial Epilepsy, Seizures
Interventions
Cadwell High-Speed Magnetoelectric Stimulator, Magpro High-Speed Magnetoelectric Stimulator
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Depression, Epilepsy
Interventions
sertraline, cognitive behavior therapy
Drug · Behavioral
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
St Louis, Missouri • New York, New York
Completed Phase 4 Interventional Results available

Seizure Prophylaxis in Aneurysm Repair

NCT01801072
Conditions
Intracranial Aneurysms, Seizure
Interventions
Levetiracetam
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Covid19, SARS-CoV2 Infection
Interventions
Focal Mask
Device
Lead sponsor
Georgia Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fed Conditions

NCT00826787
Conditions
Seizures
Interventions
Levetiracetam
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Focal Seizure
Interventions
20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks, Placebo
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
18 Years to 75 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
31
States / cities
Phoenix, Arizona • Loma Linda, California • DeLand, Florida + 28 more
Conditions
PolG, Primary Mitochondrial Myopathy
Interventions
Not listed
Lead sponsor
The POLG Foundation
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
7
States / cities
San Diego, California • Aurora, Colorado • New York, New York + 4 more
Completed Phase 1Phase 2 Interventional Results available

Dosing of Levetiracetam (Keppra) in Neonates

NCT01239212
Conditions
Seizures
Interventions
levetiracetam
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Day to 30 Days
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Psychogenic Nonepileptic Seizures (PNES)
Interventions
Cognitive Rehabilitation And Functional Treatment (CRAFT)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions
NPT 2042 (bumetanide analog) or Matching Placebo
Drug
Lead sponsor
NeuroPro Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Keratoconus, Ocular Surface Disease, Pellucid Marginal Corneal Degeneration, Ectasia, Corneal Trauma, Corneal Scar, Dry Eye Syndromes, Keratoconjunctivitis Sicca, Sjogren's Syndrome
Interventions
Ocular surface optical coherence tomography
Device
Lead sponsor
Boston Sight
Other
Eligibility
21 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Needham, Massachusetts
Conditions
Drug Resistant Partial Onset Seizure
Interventions
ganaxolone
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Santa Monica, California • Lexington, Kentucky • Golden Valley, Minnesota + 2 more
Conditions
Focal Onset Seizure
Interventions
Cenobamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 15 more
Conditions
Epilepsy
Interventions
Lacosamide Tablet, Lasosamide Oral Solution, Placebo Tablet, Placebo Oral Solution
Drug · Other
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
4 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
27
States / cities
Alabaster, Alabama • Little Rock, Arkansas • Irvine, California + 23 more
Completed Phase 1Phase 2 Interventional Results available

Determination of Absorption and Elimination of Lamotrigine-XR

NCT00789113
Conditions
Epilepsy, Seizures, Bipolar Disorder, Bipolar Depression
Interventions
Extended Release Lamotrigine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
65 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Major Depressive Disorder
Interventions
Magstim Theta, Thymatron System IV
Device
Lead sponsor
Sarah Lisanby
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
2
States / cities
Durham, North Carolina • Dallas, Texas
Conditions
Epilepsy
Interventions
oxygen
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Recruiting Not applicable Interventional

Optimizing Brain Stimulation Parameters

NCT06617845
Conditions
Epilepsy; Seizure
Interventions
Stimulation Set A and B
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
6 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota